Exchange: NASDAQ Sector: Healthcare Industry: Medical Instruments & Supplies
Current Signal: SELL (auto-tracking)
-1.27% $4.67
America/New_York / 28 mar 2024 @ 11:17
FUNDAMENTALS | |
---|---|
MarketCap: | 229.51 mill |
EPS: | -1.430 |
P/E: | -3.27 |
Earnings Date: | May 05, 2024 |
SharesOutstanding: | 49.14 mill |
Avg Daily Volume: | 0.207 mill |
RATING 2024-03-27 |
---|
B |
Neutral |
RATINGS | ||
---|---|---|
Rating CashFlow: | Strong Sell | |
Return On Equity: | Sell | |
Return On Asset: | Neutral | |
DE: | Strong Buy | |
P/E: | Strong Sell | |
Price To Book: | Strong Buy |
QUARTER GROWTHS | ||||||
---|---|---|---|---|---|---|
3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
Revenue | ||||||
Gr.Profit | ||||||
Ebit | ||||||
Asset | ||||||
Debt |
PE RATIO: COMPANY / SECTOR |
---|
0.00x |
Company: PE -3.27 | sector: PE -3.05 |
PE RATIO: COMPANY / INDUSTRY |
---|
-0.10x |
Company: PE -3.27 | industry: PE 33.06 |
DISCOUNTED CASH FLOW VALUE |
---|
N/A |
N/A |
Expected Trading Range (DAY) |
---|
$ 4.20 - 5.10 ( +/- 9.74%) |
ATR Model: 14 days |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-03-23 | Pla Frederic | Sell | 2 006 | Common Stock |
2024-03-23 | Ramachandran Niro Ph.d | Sell | 2 006 | Common Stock |
2024-03-23 | Mckelligon Brian | Sell | 7 135 | Common Stock |
2024-03-20 | Mckelligon Brian | Sell | 7 500 | Employee Stock Option (Right to Buy) |
2024-03-20 | Mckelligon Brian | Buy | 7 500 | Common Stock |
INSIDER POWER |
---|
68.13 |
Last 99 transactions |
Buy: 5 199 597 | Sell: 927 094 |
Indicator Signals | |
---|---|
RSI 21 | |
SMA | |
Trend | |
Trend 2 | |
Trend 3 | |
MACD |
Volume Signals | |
---|---|
Price | $4.67 (-1.27% ) |
Volume | 0.0241 mill |
Avg. Vol. | 0.207 mill |
% of Avg. Vol | 11.62 % |
Signal 1: | |
Signal 2: |
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
Date | Signal | @ | Closed | % | Feb 6 - 13:14 | buy | $5.71 | N/A | Active |
---|
Akoya Biosciences, Inc., a life sciences technology company, provides spatial biology solutions focused on transforming discovery and clinical research in North America, the Asia Pacific, Europe, the Middle East, and Africa. The company offers PhenoCycler instrument, a compact bench-top fluidics system that integrates with a companion microscope to automate image acquisition; and PhenoImager platform that enables researchers to visualize, analyze, quantify, and phenotype cells in situ, in fresh frozen or FFPE tissue sections, and tissue microarrays utilizing an automated and high-throughput workflow. It also provides PhenoCycler and PhenoImager reagents; and biopharma services. In addition, the company offers Proxima, a cloud-based platform to store, analyze, and share spatial data; inForm Tissue, an automated image analysis software package for accurately visualizing and quantifying biomarkers in tissue sections; Phenoptr, which provides functions that consolidate and analyze output tables created by inForm software; and phenoptrReports, a software that generates shareable reports and visualizations based on the phenoptr output in an intuitive front-end GUI. The company was incorporated in 2015 and is headquartered in Marlborough, Massachusetts.